Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,984

Document Document Title
WO/2021/068992A1
Disclosed in the present invention is a method for producing biogas from waste liquid after diosgenin is extracted using aluminum chloride. Specifically, in a fermentation vessel, an anaerobic sludge having a volatile solids ratio of 1-3...  
WO/2021/068991A1
A method for preparing diosgenin by ternary two-phase AlCl3 hydrolysis. Dried yam powder is placed into a reaction vessel, and then a ternary, two-phase solution consisting of an aqueous aluminum chloride solution, ethanol, and petroleum...  
WO/2021/023751A1
The present invention relates to esters of Montelukast with corticosteroids, preferably with des-ciclesonide, triamcinolone, budesonide or flunisolide, pharmaceutical compositions containing the same and the use thereof in the treatment ...  
WO/2021/014348A1
The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the t...  
WO/2021/016191A1
Disclosed herein are compounds of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidan...  
WO/2020/264495A1
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...  
WO/2020/243488A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...  
WO/2020/223174A1
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cel...  
WO/2020/210907A1
The present disclosure relates to processes for recovering valuable products from Fabaceae family plant fractions, in particular from Medicago sativa ssp. The processes disclosed herein include processes for obtaining macrofibers, microf...  
WO/2020/198878A1
The present application provides compounds, compositions and methods to reduce, alleviate or treat various enteric diseases and disorders, such as inflammatory bowel disease. The compounds are xyloglucan-containing prodrugs, referred to ...  
WO/2020/185610A1
The present disclosure is concerned with taccalonolide analogs and conjugated taccalonolide analogs useful as cellular probes and in the treatment of, for example, hyperproliferative disorders such as cardiovascular diseases and cancer. ...  
WO/2020/146541A3
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/146541A2
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/128514A1
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...  
WO/2020/115371A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2020/092972A1
Provided herein are steroid sulfatase inhibitor compounds and androgen receptor inhibitor compounds that can be useful in, for example, the treatment of cancers such as prostate cancer and breast cancer. Pharmaceutical compositions and k...  
WO/2020/082527A1
Disclosed is a process for extracting saponin from a plant. The preparation step thereof comprises: 1) adding an acid or a petroleum ether solvent and an acid to saponin for hydrolysis while extracting saponin, wherein directly carrying ...  
WO/2020/069267A1
Provided herein are halogenated cholesterol analogues, including methods of making and using the same. Also provided are methods of making radiolabeled cholesterol analogues including admixing an epoxide with a fluorine-18 source under c...  
WO/2020/062883A1
The present invention relates to a derivative based on an Anemarrhenae rhizome sarsasapogenin structure, wherein the structural formula thereof is as shown in general formula I, (I). Also provided are a pharmaceutical composition of the ...  
WO/2020/068689A1
Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.  
WO/2020/025942A1
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic ...  
WO/2019/195692A1
wherein,R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. ...  
WO/2019/191637A1
Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.  
WO/2019/173499A1
Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment w...  
WO/2019/136487A3
Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.  
WO/2019/136487A2
Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.  
WO/2019/129308A1
Provided is a method for recycling steroid epoxy isomer. Reacting with a reactive metal such as lithium, sodium, and potassium in an diphenyl organic solvent so as to reduce and form conjugated double bonds; in an alkaline environment, k...  
WO/2019/129176A1
The present invention provides a sarsasapogenin derivative and a preparation method and application thereof. The derivative has a structure as shown in formula I, and the definition of each substituent is as described in the specificatio...  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2019/116070A1
The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.  
WO/2019/090405A1
The invention disclosed herein is intended for the pharmaceutical industry and the area of medicine for combating flu, and relates to any medicinal-product composition that is characterized by containing ciclesonide in the composition th...  
WO/2019/081586A1
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of...  
WO/2019/080571A1
The present invention provides a method for extracting toosendanin, comprising: first washing and drying melia azedarach bark or melia azedarach seeds, grinding, and performing extraction by using a cellulase and apectinase water solutio...  
WO/2019/055493A1
A method for treating a mitogen activated protein kinase kinase/extracellular signal-regulated kinase ("MEK")-induced or an MEK-related pathology in a mammal, comprising administering a pharmaceutical composition containing an effective ...  
WO/2019/021122A3
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...  
WO/2019/023769A1
The present invention relates, most generally, to steroidal glycosides that can be used for treating skin disorders. Particularly, the invention relates to the use of certain steroidal glycosides, per se or in the form of aglycone, spiro...  
WO/2019/021122A2
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...  
WO/2019/015914A1
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) hydrogenation of the double bond and reductive opening of the epoxide of a compound of formula (II) or a salt or solvate t...  
WO/2019/006534A1
Methods, uses, compositions and kits for treating steroid-resistant chronic rhinosinusitis (CRS), including refractory CRS, in a subject, or for improving or restoring the response to anti- inflammatory sinus treatment in a patient suffe...  
WO/2018/213077A1
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are...  
WO/2018/201516A1
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...  
WO/2018/145162A1
The present invention relates to a new class of steroid saponins that have interesting biological activity. In particular the present invention relates to a class of steroid saponins in which the sugar moiety has been selectively functio...  
WO/2018/089373A9
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...  
WO/2018/121770A1
An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. The com...  
WO/2018/089373A3
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...  
WO/2017/053868A8
Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions...  
WO/2018/033939A1
Disclosed herein is an improved process for the preparation of Budesonide using Perchloric acid catalyst in water as a major medium.  
WO/2017/211820A1
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to novel intermediates useful for the preparation of DCA and pharmaceutic...  
WO/2017/210471A1
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.  
WO/2017/199036A1
The invention relates to a process for preparing a compound of general formula (la): wherein R2, Y, R4and R5are as defined herein, wherein the epoxidation is conducted using an oxidant and methyltrioxorhenium as a catalyst (MeReO3). The ...  

Matches 1 - 50 out of 1,984